Suscribirse

Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy - 04/05/16

Doi : 10.1016/S1470-2045(16)00063-2 
Jae Y Lee, MD a, , Daniel E Spratt, MD a, , Adam L Liss, MD a, b, Patrick W McLaughlin, ProfMD a, c,
a Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA 
b Agnesian Cancer Center, Fond du Lac, WI, USA 
c Assarian Cancer Center, Novi, MI, USA 

* Correspondence to: Prof Patrick W McLaughlin, University of Michigan, Assarian Cancer Center, Department of Radiation Oncology, Novi, MI 48374, USA Correspondence to: Prof Patrick W McLaughlin University of Michigan Assarian Cancer Center Department of Radiation Oncology Novi MI 48374 USA

Summary

Treatment selection for men undergoing curative treatment for prostate cancer is often a challenging decision in view of the goal of maximising cure while maintaining quality of life. Previous quality-of-life comparisons suggest that specific outcomes are associated with type of treatment (surgery vs radiation); however, the functional anatomy approach, starting with nerve-sparing prostatectomy, assumes that quality-of-life outcomes are established by anatomic preservation. Emerging applications of the functional anatomy approach for prostate radiation will ultimately allow for individualised treatments that address the normal tissue variants visible on MRI. Such approaches will encompass all essential functions affected by treatment including genitourinary, rectal, and sexual functions. In this Review, we outline the current techniques in functional anatomy-based preservation related to sexual outcomes, and outline the capacity of vessel-sparing radiotherapy to preserve sexual function in 90% of patients at the 5 year follow-up while maintaining excellent cure rates.

El texto completo de este artículo está disponible en PDF.

Esquema


© 2016  Elsevier Ltd. Reservados todos los derechos.
Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 17 - N° 5

P. e198-e208 - mai 2016 Regresar al número
Artículo precedente Artículo precedente
  • Ethical issues of clinical trials in paediatric oncology from 2003 to 2013: a systematic review
  • Jean-Claude K Dupont, Kathy Pritchard-Jones, François Doz
| Artículo siguiente Artículo siguiente
  • Under-reporting of harm in clinical trials
  • Bostjan Seruga, Arnoud J Templeton, Francisco Emilio Vera Badillo, Alberto Ocana, Eitan Amir, Ian F Tannock

¿Ya suscrito a @@106933@@ revista ?